Recent Update: 2015/1/22


Many of the patients with chronic hepatitis C develop hepatic fibrosis, which progresses into cirrhosis and then result in onset of hepatocarcinoma (HCC). In general, anti-viral therapy is applied for chronic hepatitis, but accurate estimation of the status of fibrosis is important for evaluation of the therapy outcome and identification of the patients at high risk of cirrhosis or HCC. However, such estimation has been made by biopsy, an invasive method, which is an obstacle in clinical approach, and currently available HCC markers are not suitable for early detection of HCC. We have been focusing on the phenomena that the structures of glycans on serum glycoproteins derived from the liver are altered along with the progression of hepatic diseases, and discovered a significant number of glycoproteins as feasible marker candidates of fibrosis and HCC. This project will be conducted for establishment and validity verification of the serum test system of WFA+-M2BP, a promising marker for fibrosis, with a large number of samples in various facilities aiming commercial realization, along with further search for new marker candidates of hepatic disease progression and their feasibility validations.

Project Leader

Hisashi Narimatsu, M.D., Ph.D.
Research Center for Medical Glycoscience (RCMG),
National Institute of Advanced Industrial Science and Technology (AIST), Japan


Masashi Mizokami, M.D., Ph.D.
Director General
Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Japan

Collaborators & Contributors

[1 Collaborators、2 Contributors]

Research Center for Medical Glycoscience (RCMG),
National Institute of Advanced Industrial Science and Technology (AIST), Japan
  Hiroyuki Kaji1, Ph.D.
Team Leader, Analytical Glycoproteomics Team
  Atsushi Kuno1, Ph.D.
Senior Researcher
  Akira Togayachi1, Ph.D.
Senior Researcher
  Takashi Sato1, Ph.D.
Senior Researcher
  Yuzuru Ikehara2, M.D., Ph.D.
Team Leader, Glycoproteomics Application Team
  Masanori Gotoh2, Ph.D.
Deputy Director
  Makoto Ocho2, Ph.D.
AIST Postdoctoral Researcher
Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Japan
  Masaaki Korenaga1, M.D., Ph.D.
Chief, Division of Training in Liver Diseases
  Masaya Sugiyama2, Ph.D.
Senior Researcher
Hokkaido University Graduate School of Medicine, Japan
  Akinobu Taketomi1, M.D., Ph.D.
  Moto Fukai2, M.D., Ph.D.
Assistant Professor
  Masato Fujiyoshi2, M.D., Ph.D.
Department of Hepatology, Sapporo-Kosei General Hospital, Japan
  Shuhei Hige1, M.D., Ph.D.
Chief Director
Department of Gastroenterology, Yamagata University Faculty of Medicine, Japan
  Yoshiyuki Ueno1, M.D., Ph.D.
University of Tokyo Hospital, Japan
  Hitoshi Ikeda2, M.D., Ph.D.
Deputy Director
Keio University, Japan
  Michiie Sakamoto1, M.D., Ph.D.
Japanese Red Cross Musashino Hospital, Japan
  Namiki Izumi1, M.D., Ph.D.
Vice President
  Masayuki Kurosaki2, M.D., Ph.D.
  Nobuharu Tamaki2, M.D.
Shinshu University Hospital, Japan
  Akihiro Matsumoto1, M.D., Ph.D.
Project Researcher
Juntendo University Shizuoka Hospital, Japan
  Takafumi Ichida1, M.D., Ph.D.
Vice President
  Takuya Genda2, M.D., Ph.D.
Associate Professor
Ogaki Municipal Hospital, Japan
  Takashi Kumada1, M.D., Ph.D.
Executive Vice President
  Toshifumi Tada2, M.D., Ph.D.
Medical Director
  Hidenori Toyoda2, M.D., Ph.D.
Medical Director
Nagoya City University Graduate School of Medical Sciences, Japan
  Yasuhito Tanaka1, M.D., Ph.D.
  Kentaro Matsuura2, M.D.
  Etsuko Iio2, M.D.
Aichi Medical University, Japan
  Masashi Yoneda1, M.D., Ph.D.
  Kiyoaki Ito1, M.D., Ph.D.
Associate Professor
Ikeda Municipal Hospital, Japan
  Yasuharu Imai1, M.D., Ph.D.
  Yoshiyuki Sawai2, M.D., Ph.D.
Deputy Director
  Tomohide Kurahashi2, M.D.
Kawasaki Medical School, Japan
  Keisuke Hino1, M.D., Ph.D.
  Yuichi Hara2, M.D., Ph.D.
  Sohji Nishina2, M.D., Ph.D.
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
  Masanori Abe1, M.D., Ph.D.
Associate Professor
  Teruki Miyake2, M.D., Ph.D.
Assistant Professor
Department of Surgery and Science, Kyushu Univerity, Japan
  Ken Shirabe1, M.D., Ph.D.
Associate Professor
  Shohei Yoshiya2, M.D.
  Takeo Toshima2
Nagasaki Medical Center, National Hospital Organization, Japan
  Hiroshi Yatsuhashi1, M.D., Ph.D.
Director, Clinical Research Center
  Kazumi Yamasaki2, M.D.
Chief, Liver Failure Treatment Research Laboratory
  Shigemune Bekki2, M.D.
  Ryu Sasaki2, M.D.
Fukushima Medical University, Japan
  Hiromi Ito1, Ph.D.
Assistant Professor

→ Page Top